LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...
Arthur G. Cook is Principal, ZS Associates.
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...
Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
Extensive background and on-study uptake of TTR stabilizers likely diluted the observable marginal effect of a TTR-silencing agent, complicating attribution of benefit in the intent-to-treat primary ...
FDA’s July 2025 transparency initiative published 200+ redacted CRLs across drugs, biosimilars, and devices, offering granular insight into approvability deficiencies and review logic beyond ...
The collaboration is positioned as a translational bridge for researchers and entrepreneurs, offering an end-to-end discovery ...
Approval was supported by IRAKLIA Phase III non-inferiority data comparing on-body injector subcutaneous isatuximab to weight-based IV, both combined with pomalidomide and dexamethasone in R/R myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results